Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | CHIP and implications for myeloproliferative neoplasms

Rafael Bejar • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, gives a presentation on clonal hematopoiesis of indeterminate potential (CHIP) and implications for myeloproliferative neoplasms (MPNs) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Rafael Bejar

The role of chronic inflammation in clonal hematopoiesis and the development of MDS 1:53
The role of chronic inflammation in clonal hematopoiesis and the development of MDS
Rafael Bejar • 26 Aug 2022
The role of the innate immune system in MDS pathogenesis 1:32
The role of the innate immune system in MDS pathogenesis
Rafael Bejar • 26 Aug 2022
The importance of genomic testing in MPNs and other myeloid malignancies 1:45
The importance of genomic testing in MPNs and other myeloid malignancies
Rafael Bejar • 26 Aug 2022
Using CHIP to encourage early intervention in disease 1:29
Using CHIP to encourage early intervention in disease
Rafael Bejar • 26 Aug 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals